Mineralys Therapeutics Inc
MLYS45.423USD
+0.923+2.08%
시장 운영 시간 （ET）시세는 15분 지연됩니다
2.99B시가총액
손실P/E TTM
자세한 내용은 Mineralys Therapeutics Inc 회사
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
Mineralys Therapeutics Inc 정보
종목 코드 MLYS
회사 이름Mineralys Therapeutics Inc
상장일Feb 10, 2023
CEOMr. Jon Congleton
직원 수51
유형Ordinary Share
회계 연도 종료Feb 10
주소150 N. Radnor Chester Road
도시RADNOR
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호19087
전화18883786240
웹사이트https://mineralystx.com/
종목 코드 MLYS
상장일Feb 10, 2023
CEOMr. Jon Congleton
Mineralys Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
663.52K
-2.23%
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
51.95K
-17.16%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
Dr. Derek DiRocco, Ph.D.
Dr. Derek DiRocco, Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
663.52K
-2.23%
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
51.95K
-17.16%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Fri, Nov 7
마지막 업데이트: Fri, Nov 7
주주
주주 유형
주주
주주
비율
Catalys Pacific, LLC
11.79%
RA Capital Management, LP
9.70%
Samsara BioCapital, LLC
7.51%
SR One Capital Management, LP
4.14%
The Vanguard Group, Inc.
3.98%
기타
62.88%
주주
주주
비율
Catalys Pacific, LLC
11.79%
RA Capital Management, LP
9.70%
Samsara BioCapital, LLC
7.51%
SR One Capital Management, LP
4.14%
The Vanguard Group, Inc.
3.98%
기타
62.88%
주주 유형
주주
비율
Venture Capital
33.14%
Investment Advisor
26.65%
Hedge Fund
19.68%
Investment Advisor/Hedge Fund
14.86%
Private Equity
5.26%
Individual Investor
1.82%
Research Firm
1.60%
Bank and Trust
0.16%
Pension Fund
0.13%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
315
76.75M
101.61%
+1.04M
2025Q2
287
68.74M
105.48%
+8.03M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Catalys Pacific, LLC
8.90M
11.79%
--
--
Jun 30, 2025
RA Capital Management, LP
7.32M
9.7%
+1.18M
+19.14%
Sep 04, 2025
Samsara BioCapital, LLC
5.67M
7.51%
--
--
Sep 04, 2025
SR One Capital Management, LP
3.13M
4.14%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.32M
3.07%
+283.58K
+13.93%
Jun 30, 2025
Capital International Investors
2.90M
3.84%
+2.90M
--
Jun 30, 2025
Andera Partners S.A.S.
2.77M
3.66%
-100.00K
-3.49%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.74M
3.62%
+532.75K
+24.18%
Jun 30, 2025
Integral Health Asset Management, LLC
2.70M
3.57%
+400.00K
+17.39%
Jun 30, 2025
Capital World Investors
2.90M
3.84%
+2.90M
--
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Thu, Nov 6
마지막 업데이트: Thu, Nov 6
이름
비율
Simplify Health Care ETF
6.55%
Invesco Dorsey Wright Healthcare Momentum ETF
2.36%
Virtus LifeSci Biotech Clinical Trials ETF
1.83%
Invesco Dorsey Wright SmallCap Momentum ETF
0.54%
SPDR S&P Biotech ETF
0.31%
iShares Micro-Cap ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.26%
Invesco Nasdaq Biotechnology ETF
0.25%
Optimize Strategy Index ETF
0.24%
Vanguard US Momentum Factor ETF
0.19%
더 보기
Simplify Health Care ETF
비율6.55%
Invesco Dorsey Wright Healthcare Momentum ETF
비율2.36%
Virtus LifeSci Biotech Clinical Trials ETF
비율1.83%
Invesco Dorsey Wright SmallCap Momentum ETF
비율0.54%
SPDR S&P Biotech ETF
비율0.31%
iShares Micro-Cap ETF
비율0.28%
ProShares Ultra Nasdaq Biotechnology
비율0.26%
Invesco Nasdaq Biotechnology ETF
비율0.25%
Optimize Strategy Index ETF
비율0.24%
Vanguard US Momentum Factor ETF
비율0.19%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
